Autopsy report · NCT02380534

Use of Apheretic Technologies in Cardiovascular Disease

“Funding missing”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Pavia

Sponsor type

University, hospital or other

Conditions

Dyslipidemia

Interventions

H.E.L.P. apheresis

Participants

0

Sites

1

Countries

Italy

Trials that died the same way

• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (86% match in meaning)
• Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia
  “Funding unavailable” (86% match in meaning)
• Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
  “funding became unavailable” (86% match in meaning)
• Protandim and the Metabolic Syndrome
  “funding not available” (86% match in meaning)
• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
  “Funding was not available” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.